Heart Failure

Data show substantially reductions in cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death following fixed-dose combination treatment strategies.

Data show lower incidence of CV events following intensive treatment with a systolic blood pressure target of 110 to 130 mm Hg compared to standard treatment.

Data show oral anticoagulation following atrial fibrillation screening was initiated in 1036 participants, with 445 (29.7%) in the ILR group versus 591 (13.1%) in the control group.

Dr. Bhatt discusses the growing field of knowledge surrounding icosapent ethyl treatment in cardiovascular care.

Dr. Bhatt discusses a subgroup analysis of the REDUCE-IT to determine if icosapent ethyl reduced further ischemic events in patients with prior MI.

Net adverse clinical events occurred in 165 patients in the abbreviated-therapy group and 172 in the standard therapy group in patients at high bleeding risk after PCI.

New EMPEROR-Preserved findings show the SGLT-2 inhibitor significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status.

Risk for major bleeding was found to be higher in patients treated with aspirin, ticagrelor compared to aspirin alone.

Globally, 331 million women and 317 million men had hypertension in 1990, compared with 626 million women and 652 million men in 2019.

The updated transcatheter aortic valve replacement system incorporates a supra-annular valve design, with a redesigned catheter tip and 4 valve sizes.

Pictorial data on carotid intima-media thickness and presence of carotid plaques can improve prescription of lipid-lowering drugs.

All NOACs had a lower risk of stroke or SE compared to warfarin, including apixaban, dabigatran, and rivaroxaban.

Data show 15% of authors in this analysis reported financial associations with trial sponsors in invasive cardiovascular intervention studies.

Most common factor for hospitalizations of T2D include cardiac disorder, infections and infestations, and nervous system disorders.

The study notes the importance of follow-up monitoring of sleep apnea in patients with IH.

The technology will be implemented into Acutus Medical’s AcQMap 3D imaging and mapping systems.

Investigators believe benefit of COVID-19 vaccination outweigh the risk of myocarditis in adolescent population.

In an analysis, low GI/GL dietary patterns resulted in a reduction in HbA1c, compared with control diets with a mean difference of −0.31.

Data show the change in 24-hour ambulatory systolic blood pressure was significant between treatment and control groups with a reduction of 7.1 mm Hg.

Kelly Chin, MD discusses the recent FDA approval of selexipag IV and breakthroughs in the cardiovascular care space.

Data show the expression levels of miR-214, BNP, NT-proBNP, and sST2 were significantly higher compared to the control group.

Data show a patient aged 65 years would have an extrapolated mean event-free survival of 6.2 years for placebo and 8.3 years for dapagliflozin, at a gain of 2.1 years.

In this series of HCPLive® State of the Science, 4 experts discuss knowledge and treatment in the cardiovascular risk management space.

Data show dapagliflozin was projected to add 0.63 quality-adjusted life-years at an incremental lifetime cost of $42, 800.

Data show no significant difference in time to first heart failure rehospitalization or death compared to usual care in patients with HFrEF.